nodes	percent_of_prediction	percent_of_DWPC	metapath
Conivaptan—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.146	0.282	CbGbCtD
Conivaptan—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0989	0.19	CbGbCtD
Conivaptan—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0943	0.182	CbGbCtD
Conivaptan—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0841	0.162	CbGbCtD
Conivaptan—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0493	0.0949	CbGbCtD
Conivaptan—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0466	0.0897	CbGbCtD
Conivaptan—Electrocardiogram ST segment depression—Salbutamol—chronic obstructive pulmonary disease	0.014	0.04	CcSEcCtD
Conivaptan—AVPR1A—respiratory system—chronic obstructive pulmonary disease	0.0133	0.357	CbGeAlD
Conivaptan—AVPR2—respiratory system—chronic obstructive pulmonary disease	0.011	0.296	CbGeAlD
Conivaptan—AVPR1A—lung—chronic obstructive pulmonary disease	0.00707	0.19	CbGeAlD
Conivaptan—Oral candidiasis—Tiotropium—chronic obstructive pulmonary disease	0.00657	0.0188	CcSEcCtD
Conivaptan—Pharyngolaryngeal pain—Tiotropium—chronic obstructive pulmonary disease	0.00618	0.0176	CcSEcCtD
Conivaptan—Laryngeal pain—Tiotropium—chronic obstructive pulmonary disease	0.00613	0.0175	CcSEcCtD
Conivaptan—AVPR2—lung—chronic obstructive pulmonary disease	0.00586	0.157	CbGeAlD
Conivaptan—CYP3A4—Lidocaine metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00536	0.0579	CbGpPWpGaD
Conivaptan—Oral candidiasis—Arformoterol—chronic obstructive pulmonary disease	0.0053	0.0151	CcSEcCtD
Conivaptan—Oral candidiasis—Formoterol—chronic obstructive pulmonary disease	0.0053	0.0151	CcSEcCtD
Conivaptan—Atrial fibrillation—Roflumilast—chronic obstructive pulmonary disease	0.00509	0.0145	CcSEcCtD
Conivaptan—CYP3A4—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.00474	0.0512	CbGpPWpGaD
Conivaptan—Candida infection—Tiotropium—chronic obstructive pulmonary disease	0.00399	0.0114	CcSEcCtD
Conivaptan—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—chronic obstructive pulmonary disease	0.00387	0.0418	CbGpPWpGaD
Conivaptan—Pneumonia—Roflumilast—chronic obstructive pulmonary disease	0.00374	0.0107	CcSEcCtD
Conivaptan—Phlebitis—Aminophylline—chronic obstructive pulmonary disease	0.00373	0.0106	CcSEcCtD
Conivaptan—Infestation NOS—Roflumilast—chronic obstructive pulmonary disease	0.00371	0.0106	CcSEcCtD
Conivaptan—Infestation—Roflumilast—chronic obstructive pulmonary disease	0.00371	0.0106	CcSEcCtD
Conivaptan—Polyuria—Aminophylline—chronic obstructive pulmonary disease	0.00366	0.0104	CcSEcCtD
Conivaptan—Urinary tract infection—Roflumilast—chronic obstructive pulmonary disease	0.00361	0.0103	CcSEcCtD
Conivaptan—AVPR1A—Peptide GPCRs—CXCR2—chronic obstructive pulmonary disease	0.00354	0.0382	CbGpPWpGaD
Conivaptan—AVPR2—Peptide GPCRs—CXCR2—chronic obstructive pulmonary disease	0.00351	0.0379	CbGpPWpGaD
Conivaptan—Atrial fibrillation—Aminophylline—chronic obstructive pulmonary disease	0.00339	0.00968	CcSEcCtD
Conivaptan—Candida infection—Formoterol—chronic obstructive pulmonary disease	0.00322	0.00918	CcSEcCtD
Conivaptan—Candida infection—Arformoterol—chronic obstructive pulmonary disease	0.00322	0.00918	CcSEcCtD
Conivaptan—AVPR2—Arf6 trafficking events—ADRB2—chronic obstructive pulmonary disease	0.00317	0.0342	CbGpPWpGaD
Conivaptan—Cardiac disorder—Roflumilast—chronic obstructive pulmonary disease	0.00309	0.00883	CcSEcCtD
Conivaptan—Mediastinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.003	0.00857	CcSEcCtD
Conivaptan—Hypokalaemia—Aminophylline—chronic obstructive pulmonary disease	0.00292	0.00835	CcSEcCtD
Conivaptan—Mental disorder—Roflumilast—chronic obstructive pulmonary disease	0.00292	0.00833	CcSEcCtD
Conivaptan—Malnutrition—Roflumilast—chronic obstructive pulmonary disease	0.0029	0.00828	CcSEcCtD
Conivaptan—AVPR2—G alpha (s) signalling events—PDE4A—chronic obstructive pulmonary disease	0.00288	0.0312	CbGpPWpGaD
Conivaptan—Dehydration—Tiotropium—chronic obstructive pulmonary disease	0.00282	0.00804	CcSEcCtD
Conivaptan—Atrial fibrillation—Arformoterol—chronic obstructive pulmonary disease	0.00258	0.00737	CcSEcCtD
Conivaptan—Atrial fibrillation—Formoterol—chronic obstructive pulmonary disease	0.00258	0.00737	CcSEcCtD
Conivaptan—Thirst—Montelukast—chronic obstructive pulmonary disease	0.00252	0.00718	CcSEcCtD
Conivaptan—Hypoglycaemia—Formoterol—chronic obstructive pulmonary disease	0.00251	0.00715	CcSEcCtD
Conivaptan—Hypoglycaemia—Arformoterol—chronic obstructive pulmonary disease	0.00251	0.00715	CcSEcCtD
Conivaptan—Hyperglycaemia—Aminophylline—chronic obstructive pulmonary disease	0.00251	0.00715	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Roflumilast—chronic obstructive pulmonary disease	0.00245	0.007	CcSEcCtD
Conivaptan—Atrial fibrillation—Salbutamol—chronic obstructive pulmonary disease	0.00244	0.00695	CcSEcCtD
Conivaptan—Hypoglycaemia—Salbutamol—chronic obstructive pulmonary disease	0.00237	0.00675	CcSEcCtD
Conivaptan—Hyperglycaemia—Tiotropium—chronic obstructive pulmonary disease	0.00236	0.00674	CcSEcCtD
Conivaptan—Haematuria—Aminophylline—chronic obstructive pulmonary disease	0.00236	0.00674	CcSEcCtD
Conivaptan—Infection—Roflumilast—chronic obstructive pulmonary disease	0.00235	0.00671	CcSEcCtD
Conivaptan—Nervous system disorder—Roflumilast—chronic obstructive pulmonary disease	0.00232	0.00663	CcSEcCtD
Conivaptan—Skin disorder—Roflumilast—chronic obstructive pulmonary disease	0.0023	0.00657	CcSEcCtD
Conivaptan—Dehydration—Formoterol—chronic obstructive pulmonary disease	0.00227	0.00649	CcSEcCtD
Conivaptan—Dehydration—Arformoterol—chronic obstructive pulmonary disease	0.00227	0.00649	CcSEcCtD
Conivaptan—Urinary tract infection—Tiotropium—chronic obstructive pulmonary disease	0.00227	0.00648	CcSEcCtD
Conivaptan—Hypokalaemia—Formoterol—chronic obstructive pulmonary disease	0.00223	0.00635	CcSEcCtD
Conivaptan—Hypokalaemia—Arformoterol—chronic obstructive pulmonary disease	0.00223	0.00635	CcSEcCtD
Conivaptan—Insomnia—Roflumilast—chronic obstructive pulmonary disease	0.00214	0.00611	CcSEcCtD
Conivaptan—Hypokalaemia—Salbutamol—chronic obstructive pulmonary disease	0.0021	0.006	CcSEcCtD
Conivaptan—Urinary tract disorder—Tiotropium—chronic obstructive pulmonary disease	0.00207	0.00591	CcSEcCtD
Conivaptan—Oedema peripheral—Tiotropium—chronic obstructive pulmonary disease	0.00207	0.00589	CcSEcCtD
Conivaptan—Urethral disorder—Tiotropium—chronic obstructive pulmonary disease	0.00206	0.00586	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.00204	0.00584	CcSEcCtD
Conivaptan—Constipation—Roflumilast—chronic obstructive pulmonary disease	0.00203	0.00578	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.00198	0.0214	CbGpPWpGaD
Conivaptan—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00197	0.0212	CbGpPWpGaD
Conivaptan—Feeling abnormal—Roflumilast—chronic obstructive pulmonary disease	0.00195	0.00557	CcSEcCtD
Conivaptan—Hyperglycaemia—Arformoterol—chronic obstructive pulmonary disease	0.00191	0.00544	CcSEcCtD
Conivaptan—Hyperglycaemia—Formoterol—chronic obstructive pulmonary disease	0.00191	0.00544	CcSEcCtD
Conivaptan—Angiopathy—Tiotropium—chronic obstructive pulmonary disease	0.0019	0.00543	CcSEcCtD
Conivaptan—Mediastinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00189	0.00539	CcSEcCtD
Conivaptan—Pneumonia—Montelukast—chronic obstructive pulmonary disease	0.00186	0.0053	CcSEcCtD
Conivaptan—Infestation NOS—Montelukast—chronic obstructive pulmonary disease	0.00185	0.00527	CcSEcCtD
Conivaptan—Infestation—Montelukast—chronic obstructive pulmonary disease	0.00185	0.00527	CcSEcCtD
Conivaptan—Mental disorder—Tiotropium—chronic obstructive pulmonary disease	0.00184	0.00524	CcSEcCtD
Conivaptan—Urinary tract infection—Formoterol—chronic obstructive pulmonary disease	0.00183	0.00523	CcSEcCtD
Conivaptan—Urinary tract infection—Arformoterol—chronic obstructive pulmonary disease	0.00183	0.00523	CcSEcCtD
Conivaptan—Malnutrition—Tiotropium—chronic obstructive pulmonary disease	0.00183	0.00521	CcSEcCtD
Conivaptan—Hyperglycaemia—Salbutamol—chronic obstructive pulmonary disease	0.0018	0.00514	CcSEcCtD
Conivaptan—Haematuria—Arformoterol—chronic obstructive pulmonary disease	0.0018	0.00513	CcSEcCtD
Conivaptan—Haematuria—Formoterol—chronic obstructive pulmonary disease	0.0018	0.00513	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.00177	0.0191	CbGpPWpGaD
Conivaptan—Urinary tract infection—Salbutamol—chronic obstructive pulmonary disease	0.00173	0.00494	CcSEcCtD
Conivaptan—Haematuria—Salbutamol—chronic obstructive pulmonary disease	0.0017	0.00484	CcSEcCtD
Conivaptan—Urinary tract disorder—Formoterol—chronic obstructive pulmonary disease	0.00167	0.00477	CcSEcCtD
Conivaptan—Urinary tract disorder—Arformoterol—chronic obstructive pulmonary disease	0.00167	0.00477	CcSEcCtD
Conivaptan—Oedema peripheral—Arformoterol—chronic obstructive pulmonary disease	0.00167	0.00476	CcSEcCtD
Conivaptan—Oedema peripheral—Formoterol—chronic obstructive pulmonary disease	0.00167	0.00476	CcSEcCtD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—CXCR2—chronic obstructive pulmonary disease	0.00166	0.018	CbGpPWpGaD
Conivaptan—Urethral disorder—Formoterol—chronic obstructive pulmonary disease	0.00166	0.00473	CcSEcCtD
Conivaptan—Urethral disorder—Arformoterol—chronic obstructive pulmonary disease	0.00166	0.00473	CcSEcCtD
Conivaptan—AVPR2—Peptide ligand-binding receptors—CXCR2—chronic obstructive pulmonary disease	0.00165	0.0178	CbGpPWpGaD
Conivaptan—Urinary tract disorder—Montelukast—chronic obstructive pulmonary disease	0.00164	0.00467	CcSEcCtD
Conivaptan—Urethral disorder—Montelukast—chronic obstructive pulmonary disease	0.00162	0.00464	CcSEcCtD
Conivaptan—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.00162	0.00462	CcSEcCtD
Conivaptan—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.00158	0.0045	CcSEcCtD
Conivaptan—Hypertension—Tiotropium—chronic obstructive pulmonary disease	0.00158	0.0045	CcSEcCtD
Conivaptan—Cardiac disorder—Arformoterol—chronic obstructive pulmonary disease	0.00157	0.00448	CcSEcCtD
Conivaptan—Cardiac disorder—Formoterol—chronic obstructive pulmonary disease	0.00157	0.00448	CcSEcCtD
Conivaptan—Infection—Aminophylline—chronic obstructive pulmonary disease	0.00157	0.00448	CcSEcCtD
Conivaptan—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.00157	0.00447	CcSEcCtD
Conivaptan—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.00155	0.00442	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.00154	0.0044	CcSEcCtD
Conivaptan—Cardiac disorder—Montelukast—chronic obstructive pulmonary disease	0.00154	0.00439	CcSEcCtD
Conivaptan—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00153	0.00435	CcSEcCtD
Conivaptan—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00153	0.00435	CcSEcCtD
Conivaptan—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.00152	0.00434	CcSEcCtD
Conivaptan—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.00151	0.0163	CbGpPWpGaD
Conivaptan—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.00151	0.0043	CcSEcCtD
Conivaptan—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00149	0.00426	CcSEcCtD
Conivaptan—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00148	0.00423	CcSEcCtD
Conivaptan—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.00148	0.00423	CcSEcCtD
Conivaptan—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.00148	0.00423	CcSEcCtD
Conivaptan—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.00148	0.00423	CcSEcCtD
Conivaptan—Infection—Tiotropium—chronic obstructive pulmonary disease	0.00148	0.00422	CcSEcCtD
Conivaptan—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.00148	0.00421	CcSEcCtD
Conivaptan—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.00147	0.0042	CcSEcCtD
Conivaptan—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.00147	0.0042	CcSEcCtD
Conivaptan—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.00146	0.00417	CcSEcCtD
Conivaptan—AVPR2—G alpha (s) signalling events—ADRB2—chronic obstructive pulmonary disease	0.00146	0.0158	CbGpPWpGaD
Conivaptan—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.00145	0.00414	CcSEcCtD
Conivaptan—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.00145	0.00414	CcSEcCtD
Conivaptan—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.00145	0.00413	CcSEcCtD
Conivaptan—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00144	0.00411	CcSEcCtD
Conivaptan—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.00143	0.00408	CcSEcCtD
Conivaptan—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.00141	0.00401	CcSEcCtD
Conivaptan—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.0014	0.00399	CcSEcCtD
Conivaptan—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.00139	0.00397	CcSEcCtD
Conivaptan—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.00135	0.00384	CcSEcCtD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.0013	0.0141	CbGpPWpGaD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.00129	0.014	CbGpPWpGaD
Conivaptan—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00129	0.00367	CcSEcCtD
Conivaptan—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.00127	0.00363	CcSEcCtD
Conivaptan—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.00127	0.00363	CcSEcCtD
Conivaptan—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.00127	0.00363	CcSEcCtD
Conivaptan—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.00125	0.00356	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.00125	0.00355	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.00125	0.00355	CcSEcCtD
Conivaptan—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.00123	0.0035	CcSEcCtD
Conivaptan—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.00123	0.0035	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.00122	0.00348	CcSEcCtD
Conivaptan—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.0012	0.00343	CcSEcCtD
Conivaptan—Infection—Formoterol—chronic obstructive pulmonary disease	0.00119	0.00341	CcSEcCtD
Conivaptan—Infection—Arformoterol—chronic obstructive pulmonary disease	0.00119	0.00341	CcSEcCtD
Conivaptan—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00118	0.00336	CcSEcCtD
Conivaptan—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.00118	0.00336	CcSEcCtD
Conivaptan—Infection—Montelukast—chronic obstructive pulmonary disease	0.00117	0.00334	CcSEcCtD
Conivaptan—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00117	0.0126	CbGpPWpGaD
Conivaptan—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.00117	0.00333	CcSEcCtD
Conivaptan—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.00117	0.00333	CcSEcCtD
Conivaptan—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.00116	0.0033	CcSEcCtD
Conivaptan—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.00115	0.0033	CcSEcCtD
Conivaptan—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.00115	0.00328	CcSEcCtD
Conivaptan—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.00114	0.00326	CcSEcCtD
Conivaptan—Infection—Salbutamol—chronic obstructive pulmonary disease	0.00113	0.00322	CcSEcCtD
Conivaptan—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.00112	0.00321	CcSEcCtD
Conivaptan—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.00112	0.00321	CcSEcCtD
Conivaptan—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.00112	0.00319	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.00112	0.0121	CbGpPWpGaD
Conivaptan—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00111	0.00318	CcSEcCtD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.00111	0.012	CbGpPWpGaD
Conivaptan—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.0011	0.00315	CcSEcCtD
Conivaptan—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.00109	0.0031	CcSEcCtD
Conivaptan—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.00109	0.0031	CcSEcCtD
Conivaptan—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00108	0.00308	CcSEcCtD
Conivaptan—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.00107	0.00304	CcSEcCtD
Conivaptan—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.00106	0.00303	CcSEcCtD
Conivaptan—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.00105	0.00301	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00104	0.00296	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00104	0.00296	CcSEcCtD
Conivaptan—Constipation—Formoterol—chronic obstructive pulmonary disease	0.00103	0.00293	CcSEcCtD
Conivaptan—Pain—Formoterol—chronic obstructive pulmonary disease	0.00103	0.00293	CcSEcCtD
Conivaptan—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.00103	0.00293	CcSEcCtD
Conivaptan—Pain—Arformoterol—chronic obstructive pulmonary disease	0.00103	0.00293	CcSEcCtD
Conivaptan—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.00103	0.00293	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00102	0.0029	CcSEcCtD
Conivaptan—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.00102	0.011	CbGpPWpGaD
Conivaptan—Pain—Montelukast—chronic obstructive pulmonary disease	0.00101	0.00287	CcSEcCtD
Conivaptan—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.001	0.00287	CcSEcCtD
Conivaptan—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000991	0.00283	CcSEcCtD
Conivaptan—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000991	0.00283	CcSEcCtD
Conivaptan—Headache—Aminophylline—chronic obstructive pulmonary disease	0.00099	0.00282	CcSEcCtD
Conivaptan—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	0.000986	0.00281	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00098	0.0028	CcSEcCtD
Conivaptan—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000971	0.00277	CcSEcCtD
Conivaptan—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000971	0.00277	CcSEcCtD
Conivaptan—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.00095	0.00271	CcSEcCtD
Conivaptan—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.00095	0.00271	CcSEcCtD
Conivaptan—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000947	0.0027	CcSEcCtD
Conivaptan—AVPR1A—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.000945	0.0102	CbGpPWpGaD
Conivaptan—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000938	0.00268	CcSEcCtD
Conivaptan—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000935	0.00267	CcSEcCtD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—EDN1—chronic obstructive pulmonary disease	0.000933	0.0101	CbGpPWpGaD
Conivaptan—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000933	0.00266	CcSEcCtD
Conivaptan—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000931	0.00266	CcSEcCtD
Conivaptan—AVPR2—Peptide ligand-binding receptors—EDN1—chronic obstructive pulmonary disease	0.000927	0.01	CbGpPWpGaD
Conivaptan—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000924	0.00998	CbGpPWpGaD
Conivaptan—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000897	0.00256	CcSEcCtD
Conivaptan—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000885	0.00955	CbGpPWpGaD
Conivaptan—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000885	0.00252	CcSEcCtD
Conivaptan—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000876	0.0025	CcSEcCtD
Conivaptan—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000851	0.00243	CcSEcCtD
Conivaptan—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000851	0.00243	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.00085	0.00918	CbGpPWpGaD
Conivaptan—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000849	0.00917	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.000845	0.00913	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000844	0.00912	CbGpPWpGaD
Conivaptan—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000833	0.00238	CcSEcCtD
Conivaptan—AVPR1A—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.000827	0.00893	CbGpPWpGaD
Conivaptan—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000823	0.00235	CcSEcCtD
Conivaptan—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000823	0.00235	CcSEcCtD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000818	0.00883	CbGpPWpGaD
Conivaptan—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000817	0.00882	CbGpPWpGaD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000812	0.00877	CbGpPWpGaD
Conivaptan—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000806	0.0023	CcSEcCtD
Conivaptan—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000803	0.00229	CcSEcCtD
Conivaptan—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000798	0.00228	CcSEcCtD
Conivaptan—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000777	0.00222	CcSEcCtD
Conivaptan—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000764	0.00218	CcSEcCtD
Conivaptan—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000764	0.00218	CcSEcCtD
Conivaptan—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000753	0.00215	CcSEcCtD
Conivaptan—Headache—Formoterol—chronic obstructive pulmonary disease	0.000753	0.00215	CcSEcCtD
Conivaptan—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.00075	0.00214	CcSEcCtD
Conivaptan—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000749	0.00214	CcSEcCtD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.00074	0.00799	CbGpPWpGaD
Conivaptan—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000738	0.00797	CbGpPWpGaD
Conivaptan—Headache—Montelukast—chronic obstructive pulmonary disease	0.000738	0.0021	CcSEcCtD
Conivaptan—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000722	0.00206	CcSEcCtD
Conivaptan—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000714	0.00204	CcSEcCtD
Conivaptan—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000714	0.00204	CcSEcCtD
Conivaptan—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000711	0.00203	CcSEcCtD
Conivaptan—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000708	0.00765	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000701	0.00756	CbGpPWpGaD
Conivaptan—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000699	0.002	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000697	0.00752	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000695	0.00751	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000692	0.00747	CbGpPWpGaD
Conivaptan—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000689	0.00197	CcSEcCtD
Conivaptan—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000674	0.00192	CcSEcCtD
Conivaptan—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000671	0.00725	CbGpPWpGaD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000639	0.0069	CbGpPWpGaD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000635	0.00685	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000626	0.00676	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000621	0.00671	CbGpPWpGaD
Conivaptan—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000617	0.00666	CbGpPWpGaD
Conivaptan—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000604	0.00172	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000596	0.00644	CbGpPWpGaD
Conivaptan—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000593	0.00641	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000592	0.00639	CbGpPWpGaD
Conivaptan—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000589	0.00168	CcSEcCtD
Conivaptan—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000583	0.00166	CcSEcCtD
Conivaptan—Erythema—Prednisone—chronic obstructive pulmonary disease	0.00058	0.00165	CcSEcCtD
Conivaptan—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.00058	0.00165	CcSEcCtD
Conivaptan—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000557	0.00159	CcSEcCtD
Conivaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000556	0.006	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000548	0.00591	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000544	0.00587	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000541	0.00585	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000537	0.0058	CbGpPWpGaD
Conivaptan—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000537	0.00153	CcSEcCtD
Conivaptan—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000536	0.00153	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000533	0.00576	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.00053	0.00572	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—CXCL8—chronic obstructive pulmonary disease	0.000504	0.00545	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—CXCL8—chronic obstructive pulmonary disease	0.000501	0.00541	CbGpPWpGaD
Conivaptan—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.0005	0.00143	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.00049	0.0014	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000481	0.00519	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000477	0.00515	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000477	0.00515	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000473	0.00511	CbGpPWpGaD
Conivaptan—Infection—Prednisone—chronic obstructive pulmonary disease	0.00047	0.00134	CcSEcCtD
Conivaptan—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000464	0.00132	CcSEcCtD
Conivaptan—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.00046	0.00131	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000436	0.00471	CbGpPWpGaD
Conivaptan—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000436	0.00471	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000433	0.00468	CbGpPWpGaD
Conivaptan—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000428	0.00122	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000422	0.00456	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000419	0.00452	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000417	0.0045	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000414	0.00447	CbGpPWpGaD
Conivaptan—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000408	0.00116	CcSEcCtD
Conivaptan—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000405	0.00115	CcSEcCtD
Conivaptan—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.00039	0.00111	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.000389	0.0042	CbGpPWpGaD
Conivaptan—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000387	0.0011	CcSEcCtD
Conivaptan—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000374	0.00107	CcSEcCtD
Conivaptan—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000361	0.00389	CbGpPWpGaD
Conivaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000353	0.00381	CbGpPWpGaD
Conivaptan—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000348	0.00376	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000338	0.00365	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000336	0.00363	CbGpPWpGaD
Conivaptan—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000335	0.000955	CcSEcCtD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	0.000334	0.00361	CbGpPWpGaD
Conivaptan—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000324	0.000924	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.00032	0.00345	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000318	0.00343	CbGpPWpGaD
Conivaptan—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000317	0.00342	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000301	0.00326	CbGpPWpGaD
Conivaptan—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000301	0.000858	CcSEcCtD
Conivaptan—AVPR2—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000299	0.00323	CbGpPWpGaD
Conivaptan—Headache—Prednisone—chronic obstructive pulmonary disease	0.000296	0.000846	CcSEcCtD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000286	0.00309	CbGpPWpGaD
Conivaptan—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000281	0.000802	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000274	0.00296	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000272	0.00293	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.000269	0.00291	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.000267	0.00289	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000258	0.00278	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000258	0.00278	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	0.000257	0.00277	CbGpPWpGaD
Conivaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000256	0.00277	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000256	0.00276	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000256	0.00276	CbGpPWpGaD
Conivaptan—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000253	0.00273	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.000245	0.00264	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.000243	0.00262	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000236	0.00254	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000234	0.00253	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	0.000233	0.00252	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000214	0.00231	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000212	0.00229	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000208	0.00224	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	0.000188	0.00204	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	0.000187	0.00202	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000183	0.00197	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000181	0.00195	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—KL—chronic obstructive pulmonary disease	0.000175	0.00189	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—KL—chronic obstructive pulmonary disease	0.000174	0.00188	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	0.000162	0.00175	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	0.000161	0.00173	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000152	0.00164	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.00015	0.00162	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	0.000146	0.00157	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	0.000145	0.00156	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	0.000145	0.00156	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	0.000143	0.00155	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	0.000132	0.00143	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	0.000131	0.00142	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	0.000131	0.00142	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	0.00013	0.00141	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000127	0.00137	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	0.000126	0.00137	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	0.000126	0.00136	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000125	0.00135	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	0.000118	0.00127	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	0.000117	0.00126	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000116	0.00126	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000115	0.00124	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.00011	0.00119	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000109	0.00118	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	9.66e-05	0.00104	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	9.59e-05	0.00104	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	9.22e-05	0.000996	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	9.16e-05	0.000989	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	8.88e-05	0.000959	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	8.8e-05	0.000951	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	8.74e-05	0.000944	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.81e-05	0.000843	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.75e-05	0.000837	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.43e-05	0.000802	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.37e-05	0.000796	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.06e-05	0.000763	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.01e-05	0.000757	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.34e-05	0.000685	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.3e-05	0.00068	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	5.88e-05	0.000635	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.82e-05	0.000629	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.78e-05	0.000624	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	5.72e-05	0.000618	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.71e-05	0.000616	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.67e-05	0.000612	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	5.32e-05	0.000574	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.79e-05	0.000518	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.76e-05	0.000514	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.39e-05	0.000474	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.36e-05	0.00047	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.13e-05	0.000337	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	3.09e-05	0.000334	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	2.82e-05	0.000304	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.6e-05	0.00028	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.17e-05	0.000234	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.14e-05	0.000231	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.99e-05	0.000215	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.89e-05	0.000204	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	1.28e-05	0.000139	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	1.23e-05	0.000132	CbGpPWpGaD
